Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial
1996

Interleukin 6 in Metastatic Renal Cell Cancer

Sample size: 49 publication Evidence: low

Author Information

Author(s): JML Stouthard, H Goey, EGE de Vries, PH de Mulder, A Groenewegen, L Pronk, G Stoter, HP Sauerwein, PJM Bakker, CHN Veenhof

Primary Institution: Academic Medical Center, University of Amsterdam

Hypothesis

Can recombinant human interleukin 6 (rhIL-6) have anti-tumour effects in patients with metastatic renal cell cancer?

Conclusion

Recombinant human interleukin 6 can be safely administered on an outpatient basis, but its anti-tumour effects in metastatic renal cancer are limited.

Supporting Evidence

  • Two partial remissions were noted among the patients treated.
  • Moderate and reversible toxicity was observed, mainly fever and flu-like symptoms.
  • Baseline plasma IL-6 concentrations did not correlate with tumour behaviour.

Takeaway

This study tested a medicine called interleukin 6 to see if it could help people with a type of kidney cancer. It didn't work very well, but it was safe to use.

Methodology

Patients received daily subcutaneous injections of rhIL-6 for 42 days, and their responses were evaluated based on tumour measurements.

Limitations

The study had a small sample size and limited anti-tumour responses.

Participant Demographics

Patients aged 18 to 75 with histologically verified metastatic renal cell cancer.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication